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annuloplasty to coronary artery bypass grafting in patients with
moderate ischemic mitral valve regurgitation
Alfredo Trento, MD, Sorel Goland, MD, Michele A. De Robertis, RN, and Lawrence S. C. Czer, MDDr Fattouch and colleagues present the first prospective ran-
domized trial on the very controversial group of patients
with chronic moderate ischemic mitral regurgitation (MR)
undergoing coronary artery bypass (CAB). They random-
ized 100 patients with 2þ ischemic MR to CAB alone and
combined CAB plus restrictive mitral annuloplasty. All pa-
tients had a prior myocardial infarction (MI) and decreased
ventricular function (ejection fraction [EF], 42%), New
York Heart Association (NYHA) class was 2.3, left ventric-
ular end-diastolic diameter (LVEDD) was 59 mm, and pul-
monary artery pressure was 40 mm Hg. The 5-year survival
was 88.8% in the CAB-only group and 93.7% in the com-
bined group. The combined group showed reverse remodel-
ing with resolution of MR at 5 years (mean MR grade, 0.08
 0.2; LVEDD, 52 mm; left ventricular [LV] EF, 48%; pul-
monary artery pressure, 26 mm Hg; and mean NYHA class,
0.6). The CAB-only group showed an insignificant improve-
ment in functional parameters and worsening of MR in
35%. Exercise echocardiographic analysis was basically
normal in the combined group but significantly impaired
in the CAB-only group. These results are impressive.
RETROSPECTIVE STUDIES
Previous publications have been retrospective studies that
have important limitations even when statistical analysis of
propensity-matched groups was used to compensate for
the bias related to patient selection (Table 1).1-6 One such
study was published in the past year by the Cleveland Clinic
group.1 Mihaljevic and colleagues1 reviewed 390 patients
from 1991 to 2003 with 3þ or 4þ ischemic MR. Of these,
290 underwent CAB plus mitral valve (MV) annuloplasty,
and 100 underwent CAB alone. Groups were propensity
matched by using demographics, extent of coronary artery
disease, regional wall motion, and quantitative echocardio-
graphic analysis. The 1-, 5-, and 10-year survivals were
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and 39% after CAB plus mitral annuloplasty. NYHA class
improved substantially in both groups and remained im-
proved at 5 years. Their conclusion was that MV annulo-
plasty reduces postoperative MR and improves early
symptoms compared with CAB along but does not improve
long-term functional status or survival in patients with
severe functional ischemic MR (Table 1).
We published a study of similar series2 of patients with
severe chronic ischemic MR (355 patients) who underwent
revascularization alone (n ¼ 168) and revascularization
combined with MV repair (n¼ 187). The combined surgical
group had a greater reduction in MR grade (2/4 vs 0.2). Both
groups had similar operative mortality (11% in the com-
bined group vs 4.7% in the revascularization-only group,
P ¼ .11) and actuarial survival at 5 years (44% vs 41%,
P ¼ .53). Independent predictors of long-term mortality
were older age, fewer bypass grafts, and lower EF. After ad-
justing for these variables, there was only a trend (P ¼ .08)
toward higher survival with the combined surgical proce-
dure (Table 1). These retrospective studies also indicate
that there is a significant recurrence of MR after annulo-
plasty (Table 1).3 The issue is complicated by the fact that
the retrospective reviews encompass patients who under-
went surgical treatment over a long period of time and that
the surgical techniques for mitral repair and the type of
mitral rings have changed over time, making comparisons
more difficult.
RECURRENCE OF ISCHEMIC MR
A more recent study by Braun and colleagues4 was pre-
sented at the Society of Thoracic Surgeons meeting in
2007. It was a prospective follow-up of 100 consecutive pa-
tients with severe ischemic MR undergoing restrictive mitral
annuloplasty and coronary revascularization. The surgical
technique was uniform, stringent downsizing by 2 ring sizes
(median size, 26 mm) with the Carpentier–Edwards Physio
Ring in all patients. The preoperative EF was 27%. The 5-
year survival was a remarkable 71%, and it was 80% for pa-
tients with a preoperative LVEDD of 65 mm or less. There
was a significant reduction of MR from 3.2þ to 0.8þ, and
at late follow-up, of the 75 survivors, only 1 patient had
3þMR, 11 patients had 2þMR, and 63 patients had 1þ or
no MR. Their conclusion was that for patients with a preop-
erative LVEDD of 65 mm or less, restrictive mitral annulo-
plasty with revascularization provides a cure for ischemicgery c August 2009
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shows complete success by means of restrictive mitral annu-
loplasty in patients with advanced ischemic MR (MR grade,
3.2þ; EF, 28%; Table 1). We all experience in our practice
a recurrence of MR in patients with severe type III-B MR,
specifically when eccentric jets are directed posteriorly at
the level of P3. A restrictive annuloplasty in these patients
often is unsuccessful. Several techniques have been tried
with variable success, including cutting of the secondary
chordae, Alfieri edge-to-edge repair, infarct plication, surgi-
cal relocation of the papillary muscles, and posterior MV
restoration. Braun and associates4 did not report the problem
of recurrence with restrictive annuloplasty alone. A reason-
able inference for patients with severe chronic ischemic MR
undergoing coronary revascularization is that they should
have an MV repair that would include a restrictive annulo-
plasty and some other repair technique for the eccentric
MR yet at the level of P3. In many patients, however, MV
annuloplasty alone will not improve long-term outcome
because the ventricular pathology is not addressed with the
MV repair. For moderate chronic ischemic MR, this is
a very aggressive approach for which there is no general
consensus.
We recently identified 83 patients who underwent revas-
cularization between 1991 and 2004 (data previously unpub-
lished). They all had reduced LV function and moderate 3þ
MR. Twenty-eight patients underwent CAB and MV repair,
and 55 underwent CAB alone. Preoperative clinical charac-
teristics of these patients were comparable. We compared
the changes in MR grade, functional class, and LVEF in
both groups.We also compared 23 propensity-matched pairs
of patients. The 1-year survival was 96% in both groups,
and the 5-year survival was 87% in the CAB plus MV repair
group and 81% in the CAB-only group. This was not statis-
tically significant (P ¼ .13). There was a significant reduc-
tion in MR grade at 1 year in the combined group versus
the CAB-only group. There was only a trend at 5 years.
This lack of sustained significance might be due to a rela-
tively small number of patients at longer follow-up. We
found a significant improvement in postoperative NYHA
class in both groups the first year after surgical intervention,
which persisted at the 5-year follow-up. There was no statis-
tically significant difference between the 2 groups (P¼ .10),
and the propensity analysis did not alter our results. Our
analysis was a small retrospective review with significant
limitations.
CLINICAL SIGNIFICANCE OF MODERATE
ISCHEMIC MR
A better way to look at the issue of moderate ischemicMR
was used by Di Mauro and colleagues,5 who compared, us-
ing propensity scores, a group of 70 patients who underwent
CAB alone in the presence of 2þ ischemic MR and LV dys-
function with a group of 70 patients who underwent CABThe Journal of Thoracic and Cbut did not have MR. The presence of moderate MR had
a significantly negative effect on survival and NYHA func-
tional class (Table 1). The same results were published by
the Cleveland Clinic group.6 The presence of moderate
ischemic MR showed a negative effect on survival among
propensity-matched patients who underwent CAB (210
TABLE 1. Literature conclusion summary
Author Conclusions
Mihaljevic and
coworkers1
Although coronary artery bypass grafting
plus mitral valve annuloplasty reduces
postoperative mitral regurgitation and
improves early symptoms compared with
coronary artery bypass grafting alone, it
does not improve long-term functional
status or survival in patients with severe
functional ischemic mitral regurgitation.
The mitral valve annuloplasty in this
setting, without addressing fundamental
ventricular pathology, is insufficient to
improve long-term clinical outcomes.
Kim and coworkers2 In patients with ischemic mitral regurgitation,
combined mitral valve repair and
revascularization resulted in less
postoperative mitral regurgitation and
similar 5-year survival when compared
with revascularization alone.
McGee and coworkers3 Although initial mitral valve replacement
would eliminate the risk of postoperative
mitral regurgitation, this strategy has been
associated with reduced survival.
Braun and coworkers4 At 4.3 years’ follow-up, intermediate-term
cutoff values for left ventricular reverse
remodeling proved to be predictors for late
mortality. For patients with a preoperative
left ventricular end-diastolic diameter of
65 mm or less, restrictive mitral
annuloplasty with revascularization
provides a cure for ischemic mitral
regurgitation and heart failure. However,
when the left ventricular end-diastolic
diameter exceeds 65 mm, outcome is poor,
and a ventricular approach should be
considered.
Di Mauro and
coworkers5
This study confirms that moderate ischemic
mitral regurgitation has an important
negative effect on survival and quality of
life of patients with severely impaired left
ventricular function treated by means of
coronary artery bypass grafting alone.
Lam and coworkers6 Moderate ischemic mitral regurgitation does
not reliably resolve with coronary artery
bypass grafting surgery alone and is
associated with reduced survival. Therefore
a mitral valve procedure might be warranted
for such patients presenting for coronary
artery bypass grafting.ardiovascular Surgery c Volume 138, Number 2 287
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well as the present work of Dr Fattouch and colleagues,
seem to indicate that restrictive annuloplasty in patients
with moderate ischemic MR and LV dysfunction improves
long-term survival and functional status and prevents the
remodeling process.
STATISTICAL PITFALLS
The results of this first prospective randomized study are
compelling, and intuitively, I tend to agree with their conclu-
sions. There are, however, several statistical pitfalls in their
study that sifgnificantly downgrade its scientific value.
The title of the paper refers to a ‘‘Prospective, random-
ized, double blinded study.’’ I agree that the study is
prospective and randomized, but it cannot be double blind.
It is very difficult to perform a double-blind study when
a surgical procedure is involved. The surgeon was not
blinded because he knew whether the patient was going to
have a ring. The cardiologist who did the echocardiographic
follow-up knew which patient had a ring and which did not
because he could see the mitral ring in the echocardiogram.
Finally, the patients were not blinded because they needed to
be told whether they had a prosthetic device in their heart.
Second, why did the author pick 50 patients in each
group? Did they do a power analysis? A randomized trial
with 50 patients per group is underpowered for overall sur-
vival at a 5-year period.
Finally, the use of the t test for comparison at follow-up on
the grades of MR by means of echocardiographic analysis
and on NYHA class is inappropriate because of comparison
of different grades of MR (1þ to 4þ) and different NYHA288 The Journal of Thoracic and Cardiovascular Surclasses. A Wilcoxon rank sum test would have been more
appropriate. There are other statistical issues related to the
small number of patients in each group. It would have also
been interesting to check the basic natriuretic peptide levels
and correlate them with the clinical status of the patients.
Despite these statistical pitfalls, the results of the study are
compelling: patients with moderate chronic MR and LV
dysfunction treated with revascularization and restrictive
mitral annuloplasty have a reverse remodeling process
with excellent 5-year survival, elimination of MR, near
normalization of LV function, normalization of pulmonary
artery pressures, and normalization of functional class with
normal exercise tolerance. Confirmation of these findings
in future studies is necessary to validate this potentially
landmark work.
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